These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1320 related articles for article (PubMed ID: 18395508)

  • 1. Functions of RANKL/RANK/OPG in bone modeling and remodeling.
    Boyce BF; Xing L
    Arch Biochem Biophys; 2008 May; 473(2):139-46. PubMed ID: 18395508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RANKL/RANK/OPG pathway.
    Boyce BF; Xing L
    Curr Osteoporos Rep; 2007 Sep; 5(3):98-104. PubMed ID: 17925190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANK/RANKL/OPG role in distraction osteogenesis.
    Pérez-Sayáns M; Somoza-Martín JM; Barros-Angueira F; Rey JM; García-García A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):679-86. PubMed ID: 20163972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Root resorption and the OPG/RANKL/RANK system: a mini review.
    Tyrovola JB; Spyropoulos MN; Makou M; Perrea D
    J Oral Sci; 2008 Dec; 50(4):367-76. PubMed ID: 19106463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANK/RANKL/OPG during orthodontic tooth movement.
    Yamaguchi M
    Orthod Craniofac Res; 2009 May; 12(2):113-9. PubMed ID: 19419454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ; Shalhoub V
    Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
    Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
    Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Osteoblast-osteoclast interaction mechanisms].
    Riancho JA; Delgado-Calle J
    Reumatol Clin; 2011 Sep; 7 Suppl 2():S1-4. PubMed ID: 21924211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of RANK, RANKL and osteoprotegerin during healing of surgically created periodontal defects in sheep.
    Baharuddin NA; Coates DE; Cullinan M; Seymour G; Duncan W
    J Periodontal Res; 2015 Apr; 50(2):211-9. PubMed ID: 24948035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.